Increased Node Dissection Improved Survival in Node-Negative Oral Cavity SCC
Higher nodal yield during definitive surgery for clinically node-negative oral cavity squamous cell carcinoma was associated with improved mortality.
Three-Weekly Cisplatin Superior to Weekly Dose in Head and Neck Cancer
Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma.
Nivolumab Maintained QOL in Advanced Squamous Cell Head and Neck Cancer
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life.
Chemo Prior to CRT in Nasopharyngeal Carcinoma May Improve Outcomes
The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.
Role for Afatinib in p16-Negative Head and Neck Cancer?
This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.
Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer
This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.
HPV Vaccination Reduced Oral HPV Infections
Prophylactic HPV vaccination significantly reduced vaccine-type oral HPV infections among young adults, according to the results of a cross-sectional study.
Immunotherapy Trials in Head and Neck Cancer
This video reviews ongoing trials testing immunotherapy for patients with head and neck cancer.
Reducing Treatment Doses in Head and Neck Cancer to Improve QOL
In this video we discuss efforts to reduce treatment doses in order to lessen long-term side effects and improve quality of life among patients with head and neck cancers.
By clicking Accept, you agree to become a member of the UBM Medica Community.